7o Capital投资1 000万港元在香港的PointFit, 该公司是一家卫生技术公司,为实时生物标志跟踪建立一个可磨损的血汗补丁,旨在向代谢和长寿市场扩展。 Seveno Capital invests $10M in Hong Kong’s PointFit, a health tech firm creating a wearable sweat patch for real-time biomarker tracking, aiming to expand into metabolic and longevity markets.

7o Capital投资1000万港元在PointFit(PointFit)上, 香港的卫生科技创业者开发了可磨损的血汗补丁, 监测实时生物标志, 如乳液, 以洞察疲劳、耐力及恢复, 而不进行血液测试。 Seveno Capital has invested $10 million in PointFit, a Hong Kong-based health tech startup developing a wearable sweat patch that monitors real-time biomarkers like lactate for insights into fatigue, endurance, and recovery without blood tests. 这项技术得到HKUST和创造性销毁实验室的支持,赢得了CES 2026创新奖,并已与全球体育组织进行了测试。 The technology, backed by HKUST and Creative Destruction Lab, won a CES 2026 Innovation Award and has been tested with global sports organizations. 这项投资标志着Seveno Capital自开设香港办事处以来的首次交易,并表明其专注于扩大亚洲健康领域的创新,并计划将PointFit平台扩展到超越耐力跟踪的代谢和寿命应用,目标是15亿美元的运动员寻求临床级数据. The investment marks Seveno Capital’s first deal since opening its Hong Kong office and signals its focus on scaling Asian healthspan innovations, with plans to expand PointFit’s platform beyond endurance tracking into metabolic and longevity applications, targeting a $15 billion segment of athletes seeking clinical-grade data.